EQS-News: More Impact AG: Subsidiary BG Braingate Technology receives Notice of Allowance from the US Patent and Trademark Office for innovative technology
|
EQS-News: More Impact AG
/ Key word(s): Patent
PRESS RELEASE More Impact AG: Subsidiary BG Braingate Technology receives Notice of Allowance from the US Patent and Trademark Office for innovative technology Frankfurt am Main, April 15, 2025 – More Impact AG (ISIN: DE000A1PG979, “More Impact”), a listed high-tech medical hub, announces that its subsidiary BG Braingate Technology GmbH (“Braingate Technology”) has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for another of its technological innovations. This means that the issuance of the patent by the US authorities is binding and absured. An important milestone for the international marketing of products based on the patented device and a special extraction process has thus been reached. The patent application relates to an innovative device and a method for the efficient, selective and gentle extraction of one or more components from biological materials, in particular cannabinoids such as the medically used CBD. The biological components obtained by the patented process can be processed accordingly and administered either via the medical inhaler or via the needleless syringe, depending on the medical indication. Dr. Karsten Behlke, Managing Director of BG Braingate Technology: “The pending issuance of the US patent is an important milestone for our international protection strategy and the commercial exploitation of our technology in the fast-growing market for plant-based active substances.” Dr. Gerald Schüssel, CEO of More Impact: “With the US patent granted in the near future, the high level of technological innovation in our portfolio companies is once again underpinned on an international scale.” With the forthcoming patent grant, More Impact and Braingate Technology are expanding their leading technological position in the field of innovative extraction processes. The forthcoming patent issuance complements the existing patent families and underpins the high-tech medical hub's claim to technological and innovative leadership. About More Impact AG Contact – Investor & Media Relations
15.04.2025 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group. |
| Language: | English |
| Company: | More Impact AG |
| Mörfelder Landstraße 277 b | |
| 60598 Frankfurt | |
| Germany | |
| Phone: | +49 69 38076661 |
| E-mail: | info@moreimpactag.de |
| Internet: | https://moreimpactag.de |
| ISIN: | DE000A1PG979, DE000A40ZTM3 |
| WKN: | A1PG97 |
| Listed: | Regulated Unofficial Market in Dusseldorf |
| EQS News ID: | 2118140 |
| End of News | EQS News Service |
|
|
2118140 15.04.2025 CET/CEST
Boersengefluester.de (BGFL) provides an overview of the key figures on sales, earnings, cash flow and dividends to help you better assess the fundamental development of the respective companies. All information is entered manually in our database - the source is the respective annual reports. All estimates for future figures are provided by BGFL.
| The most important financial data at a glance | ||||||||
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025e | ||
| Sales1 | 0,00 | 0,00 | 0,00 | 0,00 | 0,10 | 0,00 | 0,00 | |
| EBITDA1,2 | 0,00 | 0,00 | 0,00 | 0,00 | -0,37 | 0,00 | 0,00 | |
| EBITDA-Margin3 | 0,00 | 0,00 | 0,00 | 0,00 | -370,00 | 0,00 | 0,00 | |
| EBIT1,4 | 0,00 | 0,00 | 0,00 | 0,00 | -0,81 | 0,00 | 0,00 | |
| EBIT-Margin5 | 0,00 | 0,00 | 0,00 | 0,00 | -810,00 | 0,00 | 0,00 | |
| Net Profit (Loss)1 | 0,00 | 0,00 | 0,00 | 0,00 | -0,81 | 0,00 | 0,00 | |
| Net-Margin6 | 0,00 | 0,00 | 0,00 | 0,00 | -810,00 | 0,00 | 0,00 | |
| Cashflow1,7 | 0,00 | 0,00 | 0,00 | 0,00 | -0,37 | 0,00 | 0,00 | |
| Earnings per share8 | 0,00 | 0,00 | 0,00 | 0,00 | -0,01 | -0,02 | -0,02 | |
| Dividend per share8 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | |
1 in Mio. Euro; 2 EBITDA = Earnings before interest, taxes, depreciation and amortisation; 3 EBITDA in relation to sales; 4 EBIT = Earnings before interest and taxes; 5 EBIT in relation to sales; 6 Net profit (-loss) in relation to sales; 7 Cashflow from operations; 8 in Euro; Source: boersengefluester.de
Auditor: Nexia
All relevant valuation ratios, dates and other investor information on your share at a glance. Good to know: All data comes from boersengefluester.de and is updated daily. This means you are always up to date. You can get brief explanations of the key figures by moving the cursor or mouse over the relevant field.
| INVESTOR-INFORMATION | ||||||
| ©boersengefluester.de | ||||||
| More Impact | ||||||
| WKN | ISIN | Legal Type | Marketcap | IPO | Recommendation | Plus Code |
| A1PG97 | DE000A1PG979 | AG | 704,76 Mio € | 30.07.2012 | 9F2C3MM7+X6 | |
| PE 2026e | PE 10Y-Ø | BGFL-Ratio | Shiller-PE | PB | PCF | KUV |
| 54,00 | 0,00 | 0,00 | -135,00 | 10,06 | -1.925,57 | 7.118,77 |
|
Dividend '2022 in € |
Dividend '2023 in € |
Dividend '2024e in € |
Div.-Yield '2024e in % |
| 0,00 | 0,00 | 0,00 | 0,00% |
| Annual General Meeting | Q1-figures | Q2-figures | Q3-figures | Annual press conference |
| 29.08.2024 |
| Distance 60-days-line | Distance 200-days-line | Performance YtD | Performance 52 weeks | IPO |
| -6,57% | +80,97% | +171,36% | +203,37% | +116,00% |
